Pharmacological Treatment of Acute Heart Failure: Current Treatment and New Targets

2013 ◽  
Vol 94 (4) ◽  
pp. 499-508 ◽  
Author(s):  
J Pöss ◽  
A Link ◽  
M Böhm
2021 ◽  
Vol 14 (3) ◽  
pp. 261
Author(s):  
Elijah R. Haege ◽  
Hui-Chi Huang ◽  
Cheng-chen Huang

Acute heart failure (AHF) commonly arises from decompensated chronic heart failure or sudden structural and functional breakdown causing a decrease in cardiac contractility and consequently fluid accumulation and systemic congestion. Current treatment for AHF aims at reducing fluid overload and improving hemodynamic which results in quick symptom relief but still poor prognostic outcome. This study utilizes a zebrafish AHF model induced by aristolochic acid (AA) to look for natural products that could attenuate the progression of AHF. The project started off by testing nearly seventy herbal crude extracts. Two of the positive extracts were from Chinese water chestnuts and are further studied in this report. After several rounds of chromatographical chemical fractionation and biological tests, a near pure fraction, named A2-4-2-4, with several hydrophilic compounds was found to attenuate the AA-induced AHF. A2-4-2-4 appeared to inhibit inflammation and cardiac hypertrophy by reducing MAPK signaling activity. Chemical analyses revealed that the major compound in A2-4-2-4 is actually lactate. Pure sodium lactate showed attenuation of the AA-induced AHF and inflammation and cardiac hypertrophy suppression as well, suggesting that the AHF attenuation ability in A2-4-2-4 is attributable to lactate. Our studies identify lactate as a cardiac protectant and a new therapeutic agent for AHF.


2019 ◽  
Vol 13 (14) ◽  
pp. 1235-1249 ◽  
Author(s):  
Leili Pourafkari ◽  
Arezou Tajlil ◽  
Nader D Nader

Acute heart failure (AHF) is a complex disorder involving different pathophysiological pathways. In recent years, there is an increased focus on biomarkers that help with diagnosis, risk stratification and disease monitoring of AHF. Finding a reliable set of biomarkers not only improves morbidity and mortality but it can also potentially reveal the new targets of therapy. In this paper, we have reviewed the biomarkers found useful for the diagnosis as well as for risk stratification and prognostication in patients with AHF. We have discussed the established biomarkers for AHF including cardiac troponins and natriuretic peptides and emerging biomarkers including adiponectin, mi-RNA, sST2, Gal-3, MR-proADM, OPG, CT-proAVP and H-FABP for the purposes of making diagnosis, their use as a guide of therapy or for determination of prognosis.


2007 ◽  
Vol 9 (1) ◽  
pp. 10-21 ◽  
Author(s):  
Leonardo De Luca ◽  
Gregg C. Fonarow ◽  
Alexandre Mebazaa ◽  
David D. Shin ◽  
Sean P. Collins ◽  
...  

1999 ◽  
Vol 1 ◽  
pp. S103-S103
Author(s):  
M ALIMENTO ◽  
P BARBIER ◽  
A GRIMALDI ◽  
G BERNA ◽  
M GUAZZI

2006 ◽  
Vol 5 (1) ◽  
pp. 134-134
Author(s):  
L SCELSI ◽  
L TAVAZZI ◽  
A MAGGIONI ◽  
D LUCCI ◽  
G CACCIATORE ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document